These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 15741815)
21. Risk of glaucoma in ocular hypertension with and without pseudoexfoliation. Grødum K; Heijl A; Bengtsson B Ophthalmology; 2005 Mar; 112(3):386-90. PubMed ID: 15745763 [TBL] [Abstract][Full Text] [Related]
22. The relationship between glaucoma and pseudoexfoliation: the Blue Mountains Eye Study. Mitchell P; Wang JJ; Hourihan F Arch Ophthalmol; 1999 Oct; 117(10):1319-24. PubMed ID: 10532440 [TBL] [Abstract][Full Text] [Related]
23. Correlation between ocular pulse amplitude measured by dynamic contour tonometer and visual field defects. Vulsteke C; Stalmans I; Fieuws S; Zeyen T Graefes Arch Clin Exp Ophthalmol; 2008 Apr; 246(4):559-65. PubMed ID: 18193267 [TBL] [Abstract][Full Text] [Related]
24. Open-angle glaucoma in an urban population in southern India: the Andhra Pradesh eye disease study. Dandona L; Dandona R; Srinivas M; Mandal P; John RK; McCarty CA; Rao GN Ophthalmology; 2000 Sep; 107(9):1702-9. PubMed ID: 10964833 [TBL] [Abstract][Full Text] [Related]
25. Early Manifest Glaucoma Trial: design and baseline data. Leske MC; Heijl A; Hyman L; Bengtsson B Ophthalmology; 1999 Nov; 106(11):2144-53. PubMed ID: 10571351 [TBL] [Abstract][Full Text] [Related]
26. Risk factors for the development of glaucomatous visual field loss in ocular hypertension. Quigley HA; Enger C; Katz J; Sommer A; Scott R; Gilbert D Arch Ophthalmol; 1994 May; 112(5):644-9. PubMed ID: 8185522 [TBL] [Abstract][Full Text] [Related]
28. Long-term evaluation of ocular hypertension with primary angle closure and primary open angles. Sihota R; Selvan H; Sharma A; Gupta A; Gupta V; Dada T; Upadhyay AD Int Ophthalmol; 2019 Apr; 39(4):803-812. PubMed ID: 29508190 [TBL] [Abstract][Full Text] [Related]
29. The European glaucoma prevention study design and baseline description of the participants. Miglior S; Zeyen T; Pfeiffer N; Cunha-Vaz J; Torri V; Adamsons I; Ophthalmology; 2002 Sep; 109(9):1612-21. PubMed ID: 12208707 [TBL] [Abstract][Full Text] [Related]
30. Effect of hemodialysis on intraocular pressure and ocular perfusion pressure. Hu J; Bui KM; Patel KH; Kim H; Arruda JA; Wilensky JT; Vajaranant TS JAMA Ophthalmol; 2013 Dec; 131(12):1525-31. PubMed ID: 24232671 [TBL] [Abstract][Full Text] [Related]
31. Short-term tolerability of once-daily timolol hemihydrate 0.5%, timolol maleate in sorbate 0.5%, and generic timolol maleate gel-forming solution 0.5% in glaucoma and/or ocular hypertension: a prospective, randomized, double-masked, active-controlled, three-period crossover pilot study. Sonty S; Mundorf TK; Stewart JA; Stewart WC Clin Ther; 2009 Oct; 31(10):2063-71. PubMed ID: 19922877 [TBL] [Abstract][Full Text] [Related]
32. Relationship between intraocular pressure and rate of visual field progression in treated glaucoma. Rao HL; Addepalli UK; Jonnadula GB; Kumbar T; Senthil S; Garudadri CS J Glaucoma; 2013 Dec; 22(9):719-24. PubMed ID: 22595936 [TBL] [Abstract][Full Text] [Related]
33. Open-angle glaucoma and ocular hypertension: the Long Island Glaucoma Case-control Study. Leske MC; Warheit-Roberts L; Wu SY Ophthalmic Epidemiol; 1996 Jun; 3(2):85-96. PubMed ID: 8841060 [TBL] [Abstract][Full Text] [Related]
34. [Absolute filling defects of the optic disc in fluorescein angiograms in glaucoma--a retrospective clinical study]. Plange N; Remky A; Arend O Klin Monbl Augenheilkd; 2001 Apr; 218(4):214-21. PubMed ID: 11392265 [TBL] [Abstract][Full Text] [Related]
35. Keratometry, optic disc dimensions, and degree and progression of glaucomatous optic nerve damage. Jonas JB; Stroux A; Martus P; Budde W J Glaucoma; 2006 Jun; 15(3):206-12. PubMed ID: 16778642 [TBL] [Abstract][Full Text] [Related]
36. Deterioration of visual fields in patients with glaucoma with and without optic disc hemorrhages. Rasker MT; van den Enden A; Bakker D; Hoyng PF Arch Ophthalmol; 1997 Oct; 115(10):1257-62. PubMed ID: 9338670 [TBL] [Abstract][Full Text] [Related]
37. Incidence of glaucomatous visual field loss after two decades of follow-up: the Rotterdam Study. Springelkamp H; Wolfs RC; Ramdas WD; Hofman A; Vingerling JR; Klaver CC; Jansonius NM Eur J Epidemiol; 2017 Aug; 32(8):691-699. PubMed ID: 28608186 [TBL] [Abstract][Full Text] [Related]
38. Relationship between visual field severity and response to fixed combination dorzolamide/timolol or timolol alone. Olander KW; Galet VA; Jia G; Smugar SS; Stewart WC J Ocul Pharmacol Ther; 2009 Aug; 25(4):357-64. PubMed ID: 19441888 [TBL] [Abstract][Full Text] [Related]
39. Baseline factors predicting the risk of conversion from ocular hypertension to primary open-angle glaucoma during a 10-year follow-up. Salvetat ML; Zeppieri M; Tosoni C; Brusini P; Eye (Lond); 2016 Jun; 30(6):784-95. PubMed ID: 27174381 [TBL] [Abstract][Full Text] [Related]
40. Parapapillary chorioretinal atrophy in patients with ocular hypertension. I. An evaluation as a predictive factor for the development of glaucomatous damage. Tezel G; Kolker AE; Kass MA; Wax MB; Gordon M; Siegmund KD Arch Ophthalmol; 1997 Dec; 115(12):1503-8. PubMed ID: 9400782 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]